Dydrogesterone use in recurrent pregnancy loss and luteal phase insufficiency: a knowledge, attitude, and practice survey amongst Indian obstetricians and gynaecologists
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242813Keywords:
Recurrent pregnancy loss, Dydrogesterone, Luteal phase support, KAP surveyAbstract
Background: Oral dydrogesterone is effective in treating reproductive disorders such as recurrent pregnancy loss (RPL) and is a better option than progesterone for luteal phase support (LPS) after in-vitro fertilization (IVF). This study aimed to assess the attitude, knowledge, and practice of obstetricians and gynecologists (ObGyns) across India towards the usage of dydrogesterone in RPL and LPS in real-life setting.
Methods: A validated questionnaire-based survey was conducted among Indian ObGyns and results were expressed in percentages.
Results: 393 ObGyns participated in the survey. 61.3% of ObGyns agreed RPL is the three consecutive pregnancy losses prior to 20 weeks from the last menstrual period. With the use of dydrogesterone in RPL patients, 82.6% of ObGyns found ˃40% of patients having successful pregnancy outcomes. 37.2% of ObGyns mentioned that dydrogesterone is useful in ongoing pregnancy rates while 33% reported benefits in the live birth rate. At the risk for preterm delivery before 34 gestational weeks, 57% of ObGyns see benefits of dydrogesterone. More than 95% of ObGyns observed benefits of dydrogesterone over micronized progesterone such as good efficacy, fewer side effects, better tolerability, and improved patient compliance. 51.9% of ObGyns reported that they used dydrogesterone in combination with progesterone in LPS.
Conclusions: The present KAP survey highlights the observation, perception, and practicing behaviour of ObGyns on RPL and LPS. It also highlights the usage of dydrogesterone in aforesaid indications.
References
Guo H, Lu Q. Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):10971-85.
Coomarasamy A, Devall A, Brosens J, Quenby S, Stephenson M, Sierra S, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167-76.
Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson J, Driessen S, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020;15(11):e0241044.
Dimitriadis E, Menkhorst E, Saito S, Kutteh W, Brosens J. Recurrent pregnancy loss. Nat Rev Dis Primers. 2020;6(1):98.
Dashti S, Eftekhar M. Luteal-phase support in assisted reproductive technology: An ongoing challenge. Int J Reprod Biomed. 2021;19(9):761-72.
Bashiri A, Galperin G, Zeadna A, Baumfeld Y, Wainstock T. Increased live birth rate with dydrogesterone among patients with recurrent pregnancy loss regardless of other treatments. J Clin Med. 2023;12(5):1967.
Muneeba S Jr, Acharya N, Mohammad S. The role of dydrogesterone in the management of luteal phase defect: a comprehensive review. Cureus. 2023;15(11):e48194.
Eleje G, Ugwu E, Igbodike E, Malachy D, Nwankwo E, Ugboaja J, et al. Prevalence and associated factors of recurrent pregnancy loss in Nigeria according to different national and international criteria (ASRM/ESHRE vs. WHO/RCOG). Front Reprod Health. 2023;5:1049711.
Sultana S, Nallari P, Ananthapur V. Recurrent pregnancy loss (RPL): an overview. J Womens Heal Developm. 2020;3(3):302-15.
Sun H, Lu Y, Qi Q, Li M, Zhou J, Wang J, et al. Advanced age - a critical risk factor for recurrent miscarriage. Glob Health Med. 2023;5(5):316-8.
Kale A, Kale A, Yelikar K. A comparative, randomized control trial in patients of per vaginal bleeding comparing efficacy of oral dydrogesterone versus vaginal progesterone in successful pregnancy outcome for patients with recurrent pregnancy loss. J Obstet Gynaecol India. 2021;71(6):591-5.
Raghupathy R, Szekeres-Bartho J. Progesterone: a unique hormone with immunomodulatory roles in pregnancy. Int J Mol Sci. 2022;23(3):1333.
Vuong L, Pham T, Le K, Ly T, Le H, Nguyen D, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021;36(7):1821-31.
